This new global mega-study will involve close to 20,000 patients and requires provision of very sophisticated technological and statistical solutions, a key strength of Almac service offering. The firm has recently signed a record number of new bookings, including a mix of large global studies.
Jim Murphy, president of Almac Clinical Technologies, said: “We are seeing an increase in the number of large, global, complex trials as well as smaller adaptive clinical trials, each requiring sophisticated randomization and drug management approaches. Sponsors seem to be turning to experienced global firms, such as Almac, with strong project management expertise and technologies to make those trials successful.”